Clinical Trial Search

Primary: FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12 — 0.297; 0.191 Area Under the Curve (L) (standardized) — p=<.0001

Primary: Percentage of Participants With Pathological Complete Response (pCR) — 24.2 percentage of participants

Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients

Primary: Quality of Feeding Assistance Care Processes — 66.7; 47.2; 61.4 percentage of meal observations — p=<0.05

Primary: Daily and Comfortable Wearing Time — 8.8; 9.2 hours

Primary: Clinician Administered PTSD Scale (Pre & Posttreatment) — 30.0; 53.6 units on a scale

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0.4; 0.0 percentage of participants

Primary: Physical Function as Measured by Telephone Version of FIM — 83.7; 80.9 units on a scale

Primary: Pain 30 Minutes — 5.5; 6.2 units on a scale — p=0.386

Primary: DOCS Neurobehavioral Measure (DOCS = Disorders of Consciousness Scale) Change — 13.5; 18.9 units on a scale — p=.465

Primary: Drinking — 6; 8; 2 participants — p=<0.04

Primary: Index Knee Pain Scores on a Numeric Rating Scale (NRS) — 4.167; 4.703 units on a scale

Primary: Pain Score, Visual Analogue Pain Scores — 1.9 units on a scale

Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.27; -1.51; -1.15 percentage of glycosylated haemoglobin — p=0.011